6-bromo-1-(4-nitrophenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 哈马拉生物碱
• 英文名称: 6-bromo-1-(4-nitrophenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
• 化学式: C17H14BrN3O2
• 分子量: 372.2
• InChiKey: ZYMHGVJTPOYZQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  73.6
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Carboline derivatives useful in the treatment of cancer
  申请人：PTC Therapeutics, Inc.

  公开号：EP2298304A2

  公开（公告）日：2011-03-23

  In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor cancer, and in reducing plasma and/or tumor VEGF levels, are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the treatment of cancer, and the reduction of plasma and/or tumor VEGF levels, using the compounds of the invention.

  根据本发明，已鉴定出转录后抑制血管内皮生长因子表达的化合物，并提供了使用这些化合物的方法。在本发明的一个方面，提供了用于抑制血管内皮生长因子产生、治疗实体瘤癌症以及降低血浆和/或肿瘤血管内皮生长因子水平的化合物。在本发明的另一方面，提供了使用本发明化合物抑制 VEGF 生成、治疗癌症以及降低血浆和/或肿瘤 VEGF 水平的方法。
• Carboline derivatives useful in the inhibition of angiogenesis
  申请人：PTC Therapeutics, Inc.

  公开号：EP2431369A2

  公开（公告）日：2012-03-21

  In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the inhibition of angiogenesis, and/or in the treatment of cancer, diabetic retinopathy or exudative macular degeneration are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the inhibition of angiogenesis, and/or the treatment of cancer, diabetic retinopathy or exudative macular degeneration using the compounds of the invention.

  根据本发明，已鉴定出转录后抑制血管内皮生长因子表达的化合物，并提供了使用这些化合物的方法。在本发明的一个方面，提供了可用于抑制血管内皮生长因子产生、抑制血管生成和/或治疗癌症、糖尿病视网膜病变或渗出性黄斑变性的化合物。在本发明的另一方面，提供了使用本发明化合物抑制 VEGF 生成、抑制血管生成和/或治疗癌症、糖尿病视网膜病变或渗出性黄斑变性的方法。
• US7767689B2
  申请人：——

  公开号：US7767689B2

  公开（公告）日：2010-08-03
• [EN] CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES<br/>[FR] DÉRIVÉS DE CARBOLINE UTILISÉS DANS LE TRAITEMENT DU CANCER ET AUTRES MALADIES
  申请人：PTC THERAPEUTICS INC

  公开号：WO2008127715A1

  公开（公告）日：2008-10-23

  [EN] In accordance with the present invention, compounds are provided which are useful in a method or in the manufacture of a medicament for post-transcriptionally inhibiting the expression of VEGF in a subject in need thereof comprising inhibiting pathologically induced expression of VEGF without suppressing normal physiological VEGF expression by inhibiting pathologically induced VEGF mRNA translation without causing a statistically significant suppression of normal physiological VEGF mRNA translation.
  [FR] La présente invention concerne des composés utilisés dans un procédé ou dans la fabrication d'un médicament visant à inhiber de manière post-transcriptionnelle l'expression du facteur de croissance de l'endothélium vasculaire (VEGF) chez un sujet nécessitant un tel traitement, ledit procédé consistant à inhiber l'expression pathologiquement induite du facteur de croissance VEGF sans en supprimer l'expression physiologique normale en inhibant la traduction pathologiquement induite de l'ARNm du facteur de croissance VEGF sans entraîner de suppression statistiquement significative de la traduction physiologique normale de l'ARNm du facteur de croissance VEGF.
• [EN] METHODS FOR TREATING VIRAL CONDITIONS<br/>[FR] MÉTHODES DE TRAITEMENT D'ÉTATS VIRAUX
  申请人：PTC THERAPEUTICS INC

  公开号：WO2011150162A1

  公开（公告）日：2011-12-01

  Compounds that selectively inhibit viral replication or the production of viral RNA or DNA, viral protein or virus induced cytopathic effects and compositions comprising such Compounds are described. Also described are methods of inhibiting viral replication or the production of viral RNA or DNA, viral protein or virus induced cytopathic effects using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.